Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04042233 · ClinicalTrials.gov registry record · Phase 4
Intraosseous Vancomycin in Primary Total Hip Arthroplasty - Designing a Protocol
A Phase 4 study, sponsored by The Methodist Hospital Research Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 23
- Enrollment target
NCT04042233: Completed Phase 4 study, sponsored by The Methodist Hospital Research Institute.
NCT04042233 is a Phase 4 study that has completed, run by The Methodist Hospital Research Institute. The registered enrollment target is 23 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04042233, a Phase 4 study, has completed, sponsored by The Methodist Hospital Research Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 23 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate a novel vancomycin intraosseous administration protocol vs a standard IV vancomycin administration protocol for primary total hip arthroplasty patients.
Primary Outcome
vancomycin blood level before the time of incision - typically taken approximately 10 minutes before incision.
Interventions
- DRUG Experimental Intraosseous vancomycin 500mg in 250 mL NS
- DRUG Standard IV administration of vancomycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2019-12-31 |
| Est. Completion | 2022-09-01 |
| Phase | Phase 4 |
What the finished NCT04042233 record still lists
NCT04042233 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Experimental Intraosseous vancomycin 500mg in 250 mL NS is the first listed.
NCT04042233 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04042233 about?
NCT04042233 is a clinical study titled "Intraosseous Vancomycin in Primary Total Hip Arthroplasty - Designing a Protocol". The objective of this study is to evaluate a novel vancomycin intraosseous administration protocol vs a standard IV vancomycin administration protocol for primary total hip arthroplasty patients.
What is the current status of trial NCT04042233?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 23 participants. The study started on 2019-12-31. Estimated completion is 2022-09-01.
What interventions are being tested in trial NCT04042233?
The interventions under investigation include: Experimental Intraosseous vancomycin 500mg in 250 mL NS (DRUG), Standard IV administration of vancomycin (DRUG).
Who is sponsoring clinical trial NCT04042233?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04042233's enrollment target sits among peer trials
23 1725th of 2000 higher than 270 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI